Breast Cancer clinical trials in Kentucky

13 actively recruiting breast cancer trials at 10 sites across Kentucky.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT05929768

Sites in Kentucky:

Flaget Memorial Hospital — Bardstown, Kentucky
Baptist Health Corbin — Corbin, Kentucky
Commonwealth Cancer Center-Corbin — Corbin, Kentucky
Baptist Health Hardin — Elizabethtown, Kentucky
Baptist Health Lexington — Lexington, Kentucky

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT06876714

Sites in Kentucky:

Flaget Memorial Hospital — Bardstown, Kentucky
Commonwealth Cancer Center-Corbin — Corbin, Kentucky
Saint Joseph Hospital — Lexington, Kentucky
Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
Saint Joseph Hospital East — Lexington, Kentucky

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

E-Mindfulness Approaches for Living After Breast Cancer

NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …

Sponsor: NRG Oncology

NCT ID: NCT06748222

Sites in Kentucky:

Flaget Memorial Hospital — Bardstown, Kentucky
Saint Joseph Hospital East — Lexington, Kentucky

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positi…

Sponsor: Pfizer

NCT ID: NCT07062965

Sites in Kentucky:

University Medical Center, Inc. ; DBA UofL Health - UofL Hospital/Brown Cancer Center — Louisville, Kentucky
UofL Health Brown Cancer Center Medical Center Northeast — Louisville, Kentucky

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…

Sponsor: AstraZeneca

NCT ID: NCT05952557

Sites in Kentucky:

Research Site — Louisville, Kentucky

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…

Sponsor: AstraZeneca

NCT ID: NCT06103864

Sites in Kentucky:

Research Site — Lexington, Kentucky
Research Site — Louisville, Kentucky
Research Site — Louisville, Kentucky

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…

Sponsor: Hoffmann-La Roche

NCT ID: NCT06065748

Sites in Kentucky:

Baptist Health Lexington — Lexington, Kentucky
Baptist Health Hamburg — Lexington, Kentucky
Baptist Health Louisville — Louisville, Kentucky

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth fa…

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT06312176

Sites in Kentucky:

Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0053) — Edgewood, Kentucky

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…

Sponsor: Hoffmann-La Roche

NCT ID: NCT06790693

Sites in Kentucky:

Baptist Health Lexington — Lexington, Kentucky
Baptist Health Hamburg — Lexington, Kentucky
University of Kentucky - Markey Cancer Center — Lexington, Kentucky
University of Louisville Hospital — Louisville, Kentucky
Baptist Health Louisville — Louisville, Kentucky

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05564377

Sites in Kentucky:

Saint Joseph Hospital East — Lexington, Kentucky
University of Kentucky/Markey Cancer Center — Lexington, Kentucky
Mercy Health - Paducah Cancer Center — Paducah, Kentucky

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor …

Sponsor: Eisai Inc.

NCT ID: NCT04300556

Sites in Kentucky:

Norton Healthcare — Louisville, Kentucky

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

Study of LP-184 in Patients With Advanced Solid Tumors

The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is avai…

Sponsor: Lantern Pharma Inc.

NCT ID: NCT05933265

Sites in Kentucky:

Norton Healthcare, Inc. — Louisville, Kentucky

View on ClinicalTrials.gov →

NA Recruiting Network

Mobile Health for Adherence in Breast Cancer Patients

This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to e…

Sponsor: ECOG-ACRIN Cancer Research Group

NCT ID: NCT06112613

Sites in Kentucky:

Flaget Memorial Hospital — Bardstown, Kentucky
Commonwealth Cancer Center-Corbin — Corbin, Kentucky
Saint Joseph Hospital — Lexington, Kentucky
Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
Saint Joseph Hospital East — Lexington, Kentucky

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20